Study #2015-0728
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRK Fusion-Positive Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
BAY2757556 (Larotrectinib, Vitrakvi)
Description
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors Harboring NTRK Fusion
Study phase:
Phase II
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-759-1892
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.